It almost seems to me like BTX has been intentionally unclear about the distribution. Probably just poor communication, but also remember with Juvenescence/Insiders/Biotime retaining 65% of the spinoff, us paltry common shareholders are really just being thrown a bone here, and are probably the least of BTX’s concerns. I, too, am thinking AGE is super-intriguing here. With only 12mm shares being spun-off to common shareholders, and the rest being locked up by Juvenescence/Insiders/Biotime, I expect AGE to trade explosively on November 28th. At $3 a share, that’s only $36mm in market cap available to trade, and I would bet that less than half of that (call it $10mm) will actually be for sale. On high volume days, BTX trades nearly that many dollars in a single day, and November 28th is certain to be a high volume day. And God forbid a biotech fund, hedge fund or private office wants in on the action as long-term holder.....I think we may find out quickly whether AGE is the real deal or not.
All this said, we know BTX share price is going to take a hit (about 30 cents I guess, if you figure 12mm shares spun off at $3.00) on the day AGE shares get locked in by BTX shareholders, whichever day it actually is.
News 
Market Data 
Discover 
